TLSI Stock Analysis: Buy, Sell, or Hold?
TLSI - TriSalus Life Sciences, Inc. Common Stock
$4.19
0.15 (3.85%)
▲
5d:
+0.6%
30d:
+28.37%
90d:
+7.58%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TLSI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TLSI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: TLSI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: TLSI is currently trading at $4.18, which is considered extended relative to its 30-day fair value range of $3.16 to $3.93.
Technical Outlook: Technically, TLSI is in a downtrend. The price is approaching resistance at $3.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: TLSI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.80 (+118.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLSI is in a downtrend. The price is approaching resistance at $3.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: TLSI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.80 (+118.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.16 -
$3.93
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.5% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 118.4% below Wall St target ($8.80)
Trading Range Analysis
30-Day Trading Range
$3.16 -
$3.93
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.05
Resistance Level
$3.68
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.12
Wall Street Target
$8.80
(+118.4%)
Revenue Growth (YoY)
-2.9%
Profit Margin
-60.9%
Share & Embed Analysis
Last updated: June 24, 2026 2:18 PM ET
Data refreshes hourly during market hours. Next update: 3:18 PM
Data refreshes hourly during market hours. Next update: 3:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLSI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Mary T Szela
SELL
15944 shares
2026-03-17
Bryan F Cox
SELL
579 shares
2026-03-16
Jodi Devlin
SELL
273 shares
2026-03-16
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 67 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$117 | 65 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 61 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 59 HOLD |
